Eli Lilly to inject $1 billion in contract manufacturing operations in India

Core Insights - Eli Lilly and Company is investing over $1 billion (approximately ₹8,900 crore) to establish new contract manufacturing facilities in India, marking one of the largest investments in the Indian pharma sector in recent years [3] - The investment decision was influenced by Telangana's favorable ecosystem, including skilled manpower, infrastructure, and government support, despite competition from other states [1][3] - The new hub in Hyderabad will enhance Eli Lilly's manufacturing and supply capabilities, supporting its evolving portfolio and leveraging India's talent pool [1][3] Investment and Expansion - Since 2020, Eli Lilly has committed over $55 billion globally to build, expand, and acquire facilities [2][3] - The new facilities will focus on developing and manufacturing medicines for conditions such as diabetes, obesity, Alzheimer's disease, cancer, and autoimmune diseases [2][3] - The company plans to begin immediate recruitment for various roles at the new hub, including engineers, chemists, and quality control professionals [2][3] Job Creation and Local Impact - The investment will not only expand Eli Lilly's manufacturing and global medicine supply capacity in Hyderabad but also create job opportunities for local youth [2][3] - The Telangana government confirmed that all investments will be made entirely within the state [2][3]